![]() Leveraging the mechanism behind linear dichroism, molecular diagnostics company Linear Diagnostics aims to diagnose STIs in a matter of minutes, 20 minutes to be exact. More than a million cases of sexually transmitted infections (STI) are diagnosed every day. ImmunoClear can recognize whether an immunotherapy drug like durvalumab has worked, after patients with non small cell lung cancer (NSCLC) have completed chemo radiotherapy.Īdditionally, CirculoGene’s MSI Complete, which utilizes a MSI protocol that consists of eight markers, has been designed to measure the level of DNA mismatch repair deficiency demonstrated within a patient’s tumor.įounded in 2015, the biotech raised a total of $9.2 million in six funding rounds, having received $4.9 million in investments from a debt financing round in March. ![]() Therefore therapeutically, it can be used as a predictive biomarker. PD-L1 is a protein that is found in elevated amounts in cancer cells. It can also be used to keep an eye on a patient’s response to treatment, making the treatment process more efficient.įocused on cancer diagnosis, the company’s ImmunoClear is a plasma cfRNA PD-L1, a pioneering tool to evaluate the effect of treatment. Through the molecular profiling of its next generation sequencing technology TumorClear, it can aid in finding out what treatment would suit best for a specific patient, particularly with regard to oncology. CirculoGeneīased in the U.S., CirculoGene has a range of products in the field of diagnostics. Recently in June, the company announced an undisclosed investment from venture capital fund Shimadzu Future Innovation Fund L.P. The company has obtained $94 million in financing since it was set up in 2012. ![]() The company has partnered with Indian biotech MedGenome to accelerate commercialization of its HPDCR-based assays in India and the Middle East. This is done by exporting the data onto the program, which then provides comprehensive visual representation – through graphs – as well as reports of the tests. The tests are scanned with the help of ChromaCode Cloud, the company’s data analytics platform. Harnessing the technology, the molecular diagnostics company has created two products – the Tick-Borne Pathogen RUO Panel and the Multi-Drug Resistance RUO Panel. The company’s proprietary technology encodes multiple targets in a single PCR reaction. Merging machine learning with diagnostic measures, ChromaCode, a biotech based in California in the U.S., has developed HDPCR, cutting costs of next-generation sequencing (NGS) technology for diagnoses. While a good portion of the market is attributed to reagents and polymerase chain reaction tests, contemporary techniques like lateral flow assays and CRISPR-Cas-based assays made headway in the wake of the pandemic.Īs various new measures are being developed to spur quicker and more efficient diagnoses, here are six molecular diagnostics companies to look out for. ![]() The molecular diagnostics sector is a $23.2 billion industry, according to a report by Markets and Markets Research in 2022, and is poised to steadily grow by 5.4% in the next four years – to a predicted market value of $30.2 billion by 2027. Used to diagnose infections caused by human immunodeficiency viruses (HIV) as well as to detect the pregnancy hormone human chorionic gonadotropin (hCG) in urine samples through home pregnancy kits, these tests fall under a category known as molecular diagnostics. You may have heard of the enzyme-linked immunosorbent assay, more commonly known as the ELISA test, which is used to measure molecules like antibodies, antigens and proteins in biological samples.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |